Loading...
XSTOACE
Market cap26mUSD
Dec 23, Last price  
3.06SEK
1D
2.00%
1Q
26.97%
IPO
-89.56%
Name

Ascelia Pharma AB

Chart & Performance

D1W1MN
XSTO:ACE chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
14.45%
Rev. gr., 5y
%
Revenues
0k
Net income
-109m
L-16.72%
-24,392,000-37,134,000-39,905,000-98,697,000-125,903,000-131,222,000-109,288,000
CFO
-127m
L+1.22%
-20,958,000-30,333,000-36,918,000-85,527,000-116,559,000-125,263,000-126,792,000
Earnings
Feb 07, 2025

Profile

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
IPO date
Mar 13, 2019
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122019‑062018‑062017‑06
Income
Revenues
Cost of revenue
112,527
117,782
105,806
Unusual Expense (Income)
NOPBT
(112,527)
(117,782)
(105,806)
NOPBT Margin
Operating Taxes
(319)
(1,933)
(3,620)
Tax Rate
NOPAT
(112,208)
(115,849)
(102,186)
Net income
(109,288)
-16.72%
(131,222)
4.22%
(125,903)
27.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
(89)
(84)
198,172
BB yield
0.08%
0.02%
-20.14%
Debt
Debt current
884
291
1,102
Long-term debt
1,236
677
2,208
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(19,735)
(148,587)
(258,289)
Cash flow
Cash from operating activities
(126,792)
(125,263)
(116,559)
CAPEX
(65)
(38)
Cash from investing activities
46
(65)
(38)
Cash from financing activities
(936)
(1)
184,871
FCF
(112,643)
(114,656)
(102,016)
Balance
Cash
21,855
149,555
261,599
Long term investments
Excess cash
21,855
149,555
261,599
Stockholders' equity
(604,420)
(497,889)
(370,997)
Invested Capital
679,808
679,231
680,481
ROIC
ROCE
EV
Common stock shares outstanding
33,720
33,668
32,959
Price
3.37
-77.44%
14.94
-49.95%
29.85
-47.07%
Market cap
113,636
-77.41%
503,004
-48.87%
983,829
-33.60%
EV
93,901
354,417
725,540
EBITDA
(111,478)
(116,736)
(104,776)
EV/EBITDA
Interest
14
48
77
Interest/NOPBT